公司始终坚持"时间领先、技术领先"的经营理念。本次建德工厂原料药生产线通过GMP符合性检查， 再次印证公司具备领先的生产及质量管理体系，对建德工厂创新药CDMO业务从高级中间体向原料药价 值延伸具有里程碑意义，对公司持续开拓创新药原料药客户具有积极意义。 ST诺泰(688076.SH)发布公告，公司全资子公司杭州澳赛诺生物科技有限公司(简称"澳赛诺"或"建德工 厂")于近日收到浙江省药品监督管理局签发的《药品GMP符合性检查告知书》(编号：浙2026第0013 号)，澳赛诺奥格特韦钠原料药正式通过GMP符合性检查。 ...

Core Viewpoint - Aorite (605116.SH) has received the GMP compliance inspection notice from the Zhejiang Provincial Drug Administration, indicating that its production lines meet GMP standards, which will help maintain product quality and production capacity [1] Group 1: GMP Compliance - The company has passed the GMP compliance inspection for its production lines related to raw materials, specifically mometasone furoate and betamethasone [1] - The inspection covered specific workshops and production lines: Workshop 806 and 863 for mometasone furoate, and Workshop 802 for betamethasone [1] Group 2: Impact on Operations - The successful GMP compliance will support the company's ability to meet market demand for its products [1] - The inspection results are not expected to have a significant impact on the company's financial performance [1]

Core Viewpoint - China Resources Double Crane (600062.SH) announced that its subsidiary, Zhejiang Xinsai Pharmaceutical Co., Ltd., received a GMP compliance inspection notice from the Zhejiang Provincial Drug Administration for the raw materials of Fenofibrate and Azilsartan [1] Group 1 - The successful GMP compliance inspection indicates that the company's production quality management meets GMP requirements [1] - This achievement will help the company maintain stable product quality and continuous production capacity [1] - The company aims to meet the market demand for related pharmaceuticals [1]

Core Viewpoint - Unimed Pharmaceutical's subsidiary, Tianjin Unimed Biopharmaceutical Co., has been suspended from production and sales due to non-compliance with GMP standards, which may significantly impact the company's operations and could lead to further risk warnings if production does not resume within three months [1][6]. Financial Performance - In 2024, Tianjin Unimed generated revenue of 217 million yuan and a net profit of -14.0037 million yuan, accounting for 60.09% of Unimed's total revenue and 9.8% of its consolidated net profit [4]. - Unimed's 2024 annual report indicated a total revenue of 360 million yuan, a year-on-year decrease of 16.14%, and a net loss of 137 million yuan, with losses widening by 58.70% compared to the previous year [8]. Regulatory Actions - The suspension was initiated following a GMP compliance inspection by the Tianjin Municipal Drug Administration, which found that Tianjin Unimed's production practices did not meet the required standards [5][6]. - In response, Unimed has established a special rectification team to identify issues and develop a corrective action plan while cooperating with regulatory authorities to address deficiencies [7]. Market Reaction - Following the announcement, Unimed's stock price fell by 2.49%, closing at 8.24 yuan per share, with a total market capitalization of 5.436 billion yuan [9].

Core Viewpoint - Unimed Pharmaceutical announced a significant impact on its operations due to the suspension of production and sales at its subsidiary Tianjin Unimed Biopharmaceutical Co., Ltd. by the Tianjin Drug Administration, which may lead to further risk warnings if production does not resume within three months [1] Group 1: Company Operations - Tianjin Unimed is a key subsidiary of Unimed Pharmaceutical, primarily engaged in the production and sales of interferon drugs [1] - The company reported that Tianjin Unimed generated revenue of 217 million yuan in 2024, accounting for 60.09% of Unimed's total revenue, and contributed a net loss of 14.0037 million yuan, representing 9.8% of the consolidated net profit [1] - The suspension was due to non-compliance with the Good Manufacturing Practice (GMP) requirements as assessed during an inspection by the Tianjin Drug Administration [1] Group 2: Financial Performance - Unimed Pharmaceutical's 2024 annual report indicated a revenue of 360 million yuan, a year-on-year decrease of 16.14%, and a net loss of 137 million yuan, with losses widening by 58.70% compared to the previous year [2] Group 3: Market Reaction - Following the announcement, Unimed Pharmaceutical's stock price fell by 2.49%, closing at 8.24 yuan per share, with a total market capitalization of 5.436 billion yuan [3]